pTau217 (Lumipulse)-Eli Lily, Plasma

Please be advised that ordering of this test is restricted to locations participating in the Blood-Based Biomarker Sponsored Testing Program. If you are an ICL client looking to order pTau217 testing, please visit our test catalogue for more details.

Result Included

Phosphorylated Tau 217 (pTau217)

Containers

Collection Containers

Lavender top (K2-EDTA)

Volume

Sample Volume

2.0 mL

Minimum Volume

0.5 mL

Collection & Handling

Collection Instructions

Separate within 4 hours. Store and send frozen.

Stability

Ambient

Refrigerated

Frozen

3days

7 days

28 days

Rejection Criteria

Criteria

Specification

Hemolysis

Gross

Turnaround Time

18 days

Result

Name

Units

Reference Range

Conversion

Phosphorylated Tau 217 (pTau217)

ng/L

Negative: ≤0.13
Intermediate: 0.13 – 0.37
Positive: >0.37

Comment
A test result ≤0.13 ng/L is a negative result and is consistent with a negative amyloid positron tomography (PET) scan.

A negative result indicates a low likelihood that a patient’s cognitive impairment is due to Alzheimer’s disease (AD).

A test result between 0.14 ng/L and 0.37 ng/L is considered intermediate. An intermediate result does not establish a diagnosis of AD or other cognitive disorder and has increased uncertainty in regard to amyloid PET positivity.

A test result > 0.37 ng/L is positive and is consistent with a positive amylold PET scan and amyloid pathology of Alzheimer’s type. High pTau217 plasma levels alone do not establish a diagnosis of AD. Results should be interpreted in the context of other clinical signs and symptoms of AD.

Referral Location

Canada